Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept
In the last decades, we have progressively observed an improvement in therapeutic options for metastatic colorectal cancer (mCRC) treatment with a progressive prolongation of survival. mCRC prognosis still remains poor with low percentage of 5-year survival. Targeted agents have improved results obt...
Saved in:
Main Authors: | Guido Giordano, Antonio Febbraro, Michele Venditti, Serena Campidoglio, Nunzio Olivieri, Katia Raieta, Pietro Parcesepe, Giusy Carmen Imbriani, Andrea Remo, Massimo Pancione |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2014/526178 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer
by: Pietro Parcesepe, et al.
Published: (2016-01-01) -
Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer
by: Andre De Souza, et al.
Published: (2015-01-01) -
Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis
by: Selma Maacha, et al.
Published: (2020-01-01) -
Prognostic signature based on mitochondria- and angiogenesis-related genes associated with immune microenvironment of multiple myeloma
by: Dai Zhang, et al.
Published: (2025-12-01) -
12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
by: Wajiha J Kheir, et al.
Published: (2025-01-01)